4.95

2.17% -0.11

After Hours: 4.99 0.04 +0.81%

Monte Rosa Therapeutics Inc (GLUE)

Overview News Price History Option Chain Financials Why GLUE Down? Discussions Forecast

Monte Rosa Therapeutics Inc stock is traded at $4.95, with a volume of 283.90K. It is down -2.17% in the last 24 hours and down -2.94% over the past month. Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Previous Close:

$5.06

Open:

$5.05

24h Volume:

283.90K

Relative Volume:

0.41

Market Cap:

$274.33M

Revenue:

Net Income/Loss:

$-130.41M

P/E Ratio:

-2.2098

EPS:

-2.24

Net Cash Flow:

$-67.76M

1W Performance:

+10.99%

1M Performance:

-2.94%

6M Performance:

-47.78%

1Y Performance:

-7.13%

1-Day Range:

$4.86

$5.19

1-Week Range:

$4.5135

$5.47

52-Week Range:

$3.21

$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name

Monte Rosa Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (673)

Phone

617-949-2643

Address

321 HARRISON AVENUE, BOSTON

Employee

134

Twitter

Next Earnings Date

Latest SEC Filings

GLUE's Discussions on Twitter

Compare GLUE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLUE Monte Rosa Therapeutics Inc	4.95	274.33M	0	-130.41M	-67.76M	-2.24
VRTX Vertex Pharmaceuticals Inc	496.49	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.86	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	620.97	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	254.85	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.46	24.70B	3.81B	-644.79M	-669.77M	-6.24

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-15-24	Initiated	Wedbush	Outperform
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-13-22	Initiated	UBS	Buy
Aug-15-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Credit Suisse	Neutral
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Oct-14-21	Initiated	SVB Leerink	Mkt Perform

View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

07:01 AM

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer - GlobeNewswire

07:01 AM

07:00 AM

Breakthrough: New Molecular Glue Degrader Achieves 77% Tumor Shrinkage in Hard-to-Treat Breast Cancer - Stock Titan

07:00 AM

Apr 26, 2025